knowledge -WSS

knowledge

author：explore 2025-10-06 07:42:39 Page View：82

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Artificial intelligence use in health care faces greater scrutiny in 2024
Next article： The cancer drug shortage isn’t new — and neither are the solutions

explore

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

NIH tests clinical research in primary care with $30 million program

TheNIH'snewprimarycareresearchnetworkaimstoimproverepresentationinclinicalscience.AdobeFormanyAmeric

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Lilly's Alzheimer's drug donanemab backed by FDA advisers

DarronCummings/APAdviserstotheFoodandDrugAdministrationvoted11-0onMondaytorecommendtheapprovalofadru

knowledge

focus

explore

Lilly's Alzheimer's drug donanemab backed by FDA advisers